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The landscape of cancer genetics in gynaecological oncology is rapidly changing. The traditional 27 
family-history based approach has limitations and misses >50% mutation carrier. This is now being 28 
replaced by population-based approaches. The need for changing the clinical paradigm from family-29 
history based to population based BRCA1/BRCA2 testing in Ashkenazi Jews is supported by data that 30 
demonstrates population-based BRCA1/BRCA2 testing does not cause psychological harm and is cost 31 
effective. This article covers various genetic testing strategies for gynaecological cancers, including 32 
population-based approaches, panel and direct-to-consumer testing as well the need for innovative 33 
approaches to genetic counselling. Advances in genetic-testing technology and computational 34 
analytics have facilitated an integrated systems medicine approach, providing increasing potential 35 
for population-based genetic testing, risk stratification and cancer prevention. Genomic information 36 
along-with biological/computational tools will be used to deliver predictive, preventive, personalized 37 
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Introduction  46 
 47 
The traditional approach to genetic testing for high penetrance ovarian, breast and endometrial 48 
cancer gene mutations has involved testing affected individuals from high risk families through high 49 
risk cancer genetic clinics following intensive face to face genetic counselling. This family-history (FH) 50 
driven approach requires individuals and general practitioner’s to recognise and act on a significant 51 
FH. Mutation carriers, who are unaware of their FH, who do not appreciate the risk/significance of 52 
their FH, who are not proactive in seeking advice, and those who lack a strong FH (eg. from small 53 
families) get excluded from this process. It is not surprising that FH based prediction models are only 54 
moderately effective at predicting the presence of a BRCA1/BRCA2 mutation and have poor negative 55 
likelihood ratios for predicting their absence.[1] Their performance of these models falls further in 56 
population based cohorts when comparing BRCA1/2 carrier mutation rates to those in high risk 57 
families.[2] We[2] and others[3, 4] have shown that the FH based approach misses over half the at 58 
risk mutation carriers. Similar findings where significantly large proportion of identified mutation 59 
carriers lack a strong FH of cancer have been reported in testing of breast cancer (BC), ovarian 60 
cancer (OC) and endometrial cancer (EC) case series unselected for FH.[5-11] Furthermore, our 61 
analysis of data from London genetic testing laboratories indicates that only 12% of the identifiable 62 
BRCA1/BRCA2 carriers in the Ashkenazi Jewish (AJ) population have been identified over 10 years by 63 
the current family history based approach. Modelling of the current rates of detection in the NHS 64 
(National Health Service) indicates that it will take around 45 years to identify the carriers in the 65 
London Jewish population who are detectable on the basis of a family history, and that this will still 66 
miss half the people at risk. Identified BRCA1/2 and mismatch repair mutation carriers can opt for 67 
risk reducing salpingo-oophorectomy (RRSO) to reduce their ovarian cancer risk;[12, 13] 68 
MRI/mammography screening, risk-reducing mastectomy (RRM) [14], or chemoprevention with 69 
selective estrogen receptor modulators (SERM) to reduce their breast cancer risk;[15] preventive 70 
hysterectomy to reduce endometrial cancer risk;[16] as well as pre-implantation genetic diagnosis 71 
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(PGD).[17] Given the effective options available for ovarian, endometrial and breast cancer risk 72 
management and prevention in these high risk women, the points above raise serious questions 73 
about the adequacy of the current FH-based approach and suggest that a move towards new 74 
approaches for risk prediction and case identification are justified. All of the limitations described 75 
above can be overcome by a population based approach to genetic testing. 76 
 77 
Principles of Population Testing for Genetic Cancer 78 
The original 10 principles for population screening were proposed by Wilson and Jungner in 79 
1968.[18] The criteria proposed by the United Kingdom National Screening committee (UKNSC)[19] 80 
for ‘screening for late onset genetic disorders: breast and ovarian cancer’ are based on these 81 
principles. The Wilson and Jungner criteria have been modified over the years by a number of 82 
others[20-22] and adapted to genetic susceptibility for disease. Khoury et al[23] and Andermann et 83 
al[24] have presented a synthesis of emerging criteria. Table-1 summarises the published criteria 84 
into three relevant categories (a) The condition and the population, (b) the screening test and (c) the 85 
screening programme. Common and unique features of UKNSC breast and ovarian cancer[19], 86 
Khoury[23] and Andermann[24] criteria are highlighted in Table-1. Maximum overlap between the 3 87 
criteria relate to the condition and the population. Andermann criteria do not cover issues related to 88 
the screening test per se but provide more details on requirements for programme implementation. 89 
UKNSC breast and ovarian cancer criteria do not adequately cover performance of the screening 90 
test, prevalence, acceptability, cost effectiveness and evaluation of programme implementation. 91 
Criteria by Khoury et al appear most comprehensive and overlap both UKNSC breast & ovarian 92 
cancer and Andermann criteria.  93 
 94 
The above published criteria do not address some key issues for population screening of cancer gene 95 
mutations . It is essential that the penetrance of the gene be well established through validated 96 
studies before being incorporated into a screening programme. Initial data on risk estimates for new 97 
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genetic discoveries may be based on small numbers with wide confidence intervals and at times do 98 
not get confirmed in validation studies. Another important issue is understanding the impact of 99 
genetic testing on psychological health and quality of life, particularly on a population basis. While 100 
there is adequate data for high risk populations, data on this in a low-risk non-Ashkenazi Jewish 101 
population are lacking. This is needed to make an appropriate assessment balancing both risks and 102 
benefits of screening. It is important for prospective well designed implementation studies on 103 
population-based genetic testing to be undertaken prior to implementing a screening programme. 104 
Downstream management pathways should be established for at risk individuals before programme 105 
implementation. As one gene may affect more than once cancer, these should also include links to 106 
management options for other cancers at risk from one mutation, for e.g., colorectal cancer in 107 
mismatch repair mutations/ Lynch Syndrome. A population based genetic-screening programme 108 
needs to also establish and outline guidelines covering ethical and legal responsibilities such as 109 
discrimination, data protection, reporting requirements, disclosure or information sharing with 110 
family and health care providers,  sample and data storage and ownership as well as licensing/patent 111 
issues that may arise. In Table-2 we present an amalgamation of published criteria as well as some 112 
additional criteria adapted for population-based genetic testing for gynaecological cancer gene 113 
mutations. The additional criteria address some of the lacunae in previously published criteria 114 
described above.  115 
 116 
Testing in high-prevalence populations: The Ashkenazi Jewish Model 117 
The Ashkenazi Jewish (AJ) population has been used as a ‘population model’ and BRCA1/BRCA2 118 
founder mutations as a ‘disease model’, to investigate the pros and cons of a population based 119 
approach for testing for high penetrance dominant cancer gene mutations. BRCA1/BRCA2 mutations 120 
are 10-20 times more common in the AJ population (1 in 40 prevalence rate)[2, 3, 25, 26] compared 121 
to the general non-AJ population. Three BRCA1/BRCA2 mutations are commonly found in the 122 
Ashkenazi Jewish population and are called founder mutations:  in BRCA1 exons 1 and 20  123 
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(185delAG(c.68_69delAG), 5382insC(c.5266dupC)) and a segment of BRCA2 exon 11 124 
(6174delT(c.5946delT). In addition almost all the BRCA1/BRCA2 associated risk is explained by three 125 
founder mutations making testing easier and cheaper. We compared ‘population’ and ‘FH based’ 126 
approaches for BRCA1/BRCA2 testing in the Genetic Cancer Prediction through Population Screening 127 
(GCaPPS) randomised trial in the North London AJ community.[2] Participants were randomised to 128 
FH based (only individuals fulfilling strict family history criteria used in clinical genetics underwent 129 
genetic testing) and population based (all individuals irrespective of FH underwent genetic testing) 130 
testing arms. We found no difference in anxiety, depression, quality-of-life, health anxiety, distress, 131 
uncertainty and overall experience of genetic testing between FH and population-based arms. This 132 
indicates that genetic testing in a low risk population does not harm quality-of-life or psychological 133 
well-being, or cause excessive health concerns and outcomes are similar to those found in high risk 134 
populations seen in cancer genetics clinics.[27-29] Population based BRCA1/BRCA2 testing also leads 135 
to an overall reduction in anxiety, distress, and uncertainty,[2, 30, 31] though higher levels of cancer 136 
related distress in those testing positive has been reported in a single arm study.[30] While pre-test 137 
and post-test counselling was provided to all participants in the GCaPPS study, mutation carriers 138 
identified in the Israeli and Canadian studies received only post-test counselling. Data from the 139 
GCaPPS trial[2] as well as single arm Canadian[4, 30] and Israeli[3] studies confirm high acceptability 140 
as well as satisfaction with population testing amongst both men and women in the Jewish 141 
population. 142 
 143 
A key issue of concern raised by many has been that mutation penetrance with population 144 
ascertainment may be less than the penetrance estimates obtained from families attending cancer 145 
genetics clinics, which can range from 81-88% for BC and 21-65% for OC.[5, 32-34] This has been 146 
addressed by:  147 
(a) Penetrance estimates (56-64% for BC and 16% for OC) obtained from the population based 148 
Washington-Ashkenazi-Study which have been corrected for ascertainment.[35-38]  149 
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(b) Published meta-analysis integrating population and cases series based data reporting risks of 43-150 
67% for BC and 14-33% for OC.[39]  151 
(c) More recently high penetrance estimates (40-60% for BC and 53-62% for OC) irrespective of FH 152 
obtained in a large Israeli population study which corrected for previous potential biases in 153 
estimates as well as ascertainment through female carriers.[3]  154 
These data indicate that breast/ovarian cancer penetrance for AJ BRCA1/BRCA2 carriers identified 155 
through population testing and those without a strong FH are also ‘high’, though as expected these 156 
estimates are a bit lower than those obtained from individuals attending cancer genetic clinics.  157 
 158 
A health-economic evaluation is essential to balance costs and benefits in the context of setting 159 
public health policy for genetic testing for BRCA1/BRCA2 mutations. Our cost-effectiveness analysis 160 
suggests that population testing for BRCA1/BRCA2 mutations in AJ women >30 years reduces breast 161 
and ovarian cancer incidence by 0.34% and 0.62% and saves 0.101 more Quality adjusted life-years 162 
(QALYs) leading to 33 days gain in life-expectancy. We found population-based testing is extremely 163 
cost-effective compared to traditional FH based approach, with a discounted incremental cos-164 
effectiveness ratio (ICER) of ‘-£2079/QALY’.[40] This is well below the cost-effectiveness threshold 165 
used by NICE of £20,000/QALY.[41] The overall impact of such a strategy in the UK would be a 166 
reduction in ovarian cancer cases by 276 and breast cancer cases by 508, at a discounted cost saving 167 
of £3.7 million. A strength of this study is the extensive sensitivity analyses to explore model 168 
uncertainty. This included a deterministic sensitivity analysis in which all model parameters were 169 
varied widely at the extremes of their confidence intervals or range as well as a probabilistic 170 
sensitivity analysis in which all variables are varied simultaneously across their distributions. Despite 171 
a wide range of scenarios, both deterministic and 94% of simulations on probabilistic sensitivity 172 
analysis suggested that population-screening is highly cost-effective compared with the current FH 173 
based testing.[40] It’s noteworthy that a cost-saving is obtained after implementing population-174 
screening among UK AJ women over 30 years old. There are not many health care interventions that 175 
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save both lives and money! This has important implications for clinical care, population/public 176 
health, as well as providers/commissioners of health care.  177 
 178 
Successful population based mass screening strategies for logistics, costs and acceptability are best 179 
delivered outside a hospital setting. Genetic testing in a population screening programme should 180 
also be implemented outside the hospital setting. In addition, some sections/groups of the 181 
population for reasons of confidentiality do not wish to be seen going to a hospital. We have 182 
demonstrated successful recruitment to such a program using a community/high-street based 183 
model[2] and Gabai-Kapara et al[3] have successfully undertaken testing through health screening 184 
centres/ national blood banks.  185 
 186 
Implications of the AJ Model 187 
There is now good evidence to show that population testing for BRCA1/BRCA2 mutations in 188 
Ashkenazi Jews fulfils the necessary principles for population screening for genetic susceptibility of 189 
disease listed above (Table-2). Hence, there is a pressing need to change the current clinical 190 
paradigm of FH based testing for BRCA1/BRCA2 founder mutations in the Jewish population to a 191 
systematic population based approach. This has recently been advocated by us and other health 192 
professionals[40, 42] as well as charity and patient groups.[43] Such a strategy if implemented can 193 
save both lives and money. The issues that remain to be addressed are related to logistics and 194 
control which may vary by country and/or health care systems. Well defined downstream 195 
management pathways involving general practitioners, clinical genetics teams, breast surgeons and 196 
gynaecologists need to be further expanded or if necessary developed in countries where these are 197 
not yet established. 198 
 199 
Findings from the AJ model, while of direct importance for the AJ population, cannot be directly 200 
extrapolated to the rest of the general (non-Jewish) population. These may however, have 201 
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implications and be of relevance for other populations with founder mutations[44] across the world. 202 
With the falling cost of testing, as well as rising awareness, understanding, acceptance and demand 203 
for genetic testing in society, this is becoming an increasingly important area of study and 204 
investigation. Khoury et al highlighted a framework with four phases of translational research to 205 
guide the applicability of genomic  discoveries for prevention in health care,[45] and estimated that 206 
only 3% of research has been directed at downstream clinical implementation. Clearly, a lot more 207 
research is needed to assess feasibility, acceptability, impact on psychological health, cost 208 
effectiveness and applicability of such an approach in lower prevalence general populations.  209 
 210 
Testing of Population based Cancer Case Series 211 
UK[46] and other international guidelines[31, 47-49] recommend that BRCA1/2 testing should be 212 
offered at a ≥10% carrier probability/risk threshold. Recently published case series data indicate that 213 
BRCA1/BRCA2 mutations are present in 11%-23% of non-mucinous epithelial OC.[50-56] 214 
Identification of carriers has prognostic implications, and offers opportunities to access new 215 
treatment options like PARP inhibitors and enter novel clinical trials,[57, 58] as well as having 216 
implications for predictive testing and cancer prevention for family members. Hence, a number of 217 
guidelines now recommend testing for all non-mucinous epithelial OC as well as triple negative 218 
breast cancers,[48] and a number of centres in North America and some in Europe have adopted this 219 
practice. However, despite growing demand from patient groups and charities it is not yet uniformly 220 
available in clinical practice, including across most parts of England and Europe.  221 
Another example of population based case series ascertainment is the identification of Lynch 222 
Syndrome (LS). 1.6-5.9% patients with endometrial cancer (EC)[11, 59-61]  and 1.8-3.7%[62] with 223 
colorectal cancer (CRC) have mismatch repair (MMR) gene (MLH1/MSH2/MSH6/PMS2) 224 
mutations/LS. Currently Amsterdam-II[63] & Bethesda Criteria[64] are widely used to identify LS 225 
individuals.  Molecular immuno histochemistry (IHC) & microsatellite instability (MSI) analysis for ‘all’ 226 
EC and CRC cases is more effective at identifying MMR carriers/LS than Amsterdam-II/Bethesda or 227 
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modified age linked criteria alone.[62, 65-67] Reflex testing of tumour tissue is followed by pre-test 228 
counselling/ informed consent for those selected for genetic testing following IHC/MSI analysis. Such 229 
an approach would also benefit non serous epithelial OC, 20% of which are MMR deficient.[68]  230 
Despite publication of guidelines and policy recognition,[49, 69] lack of funding is currently 231 
preventing harmonised implementation of the population based cancer case series approach. This is 232 
greatly compounded by limited awareness and knowledge of these issues amongst treating 233 
clinicians, pathologists, general practitioners and the population at large. Implementation also has 234 
significant implications for expansion in cancer genetics services and downstream management 235 
pathways.  Nevertheless, as logistics for delivery get ironed out and awareness and acceptance 236 
increases, its applicability will increase and become widespread. This approach is here to stay and 237 
will expand to other relevant cancers and gene mutations.   238 
Panel Testing and Potential for Population based Risk Stratification 239 
The genomic era has heralded a rapidly changing landscape in cancer genetics. Advances in genetic 240 
testing technology with massive parallel sequencing, and big strides in computational analytics 241 
enabling synthesis of complex, large volume, cross disciplinary data has facilitated an integrated 242 
systems medicine approach, which in turn is transforming diagnostic, therapeutic and preventive 243 
healthcare strategies. In addition to the traditional high penetrance genes (e.g. BRCA1, BRCA2 and 244 
MMR genes), a number of newer intermediate/ moderate penetrance genes have been recently 245 
identified for ovarian (e.g. RAD51C, RAD51D, BRIP1),[70-72] breast (e.g. PTEN, ATM, TP53, PALB2, 246 
NBN, RAD51B, and CHEK2) and other cancers. The availability of high throughput technologies has 247 
led to multiplex panel testing becoming available in clinics. This enables testing for a number of 248 
genes leading to increased efficiency in time and costs of testing. The Office of Public Health 249 
Genomics (OPHG), Centers for Disease Control and Prevention (CDC), has described the ‘ACCE’ 250 
model/process for evaluating genetic tests, which incorporates four key components: analytic 251 
validity; clinical validity; clinical utility; and associated ethical, legal and social implications.[73, 74] 252 
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Burke and Zimmerman proposed an enhanced scheme for evaluation of genetic tests with significant 253 
emphasis on ‘clinical utility’.[75] Concern has been expressed at the lack of precise cancer risk 254 
estimates for a number of the genes which are part of these gene testing panels.[76] This lack of 255 
adequate clinical validation before regulatory approval or clinical implementation has been 256 
construed by some as being tantamount to technological misuse.  257 
 258 
Large multi-centre international collaborations (e.g. Breast Cancer Action Consortium (BCAC),[77] 259 
Ovarian Cancer Action Consortium (OCAC),[78] Consortium of Investigators of Modifiers of BRCA1/2 260 
(CIMBA),[79] Collaborative Oncological Gene-environment Study (COGS)),[80] have enabled genome 261 
wide association studies (GWAS) and large-scale genotyping efforts resulting in the discovery of 262 
numerous common genetic variants associated with cancer risk.[81, 82] Around 17 such variants 263 
have been identified for OC and 100 for BC.[76, 83] Each individual variant is associated with only a 264 
small increase in risk. However, the risk estimate for individuals who carry multiple risk alleles is 2-3 265 
fold higher than those with a low polygenic load.[83] OC and BC risk prediction algorithms 266 
incorporating a polygenic risk score (PRS) based on both the known common variants and the total 267 
hypothesised polygenotype in addition to BRCA1, BRCA2 and other familial effects have been 268 
developed to improve risk prediction.[83-85] For example, the lifetime OC risk for a BRCA1/BRCA2 269 
negative woman, with two affected first degree relatives is >5% if she is at the top 50% of the PRS 270 
distribution. In addition, a number of lifestyle, medical and personal factors such as contraceptive 271 
pill use, tubal ligation, parity, endometriosis, subfertility, age, family-history (first degree relative(s) 272 
with OC),[85] aspirin[86] and hormone replacement therapy (HRT)[87] have been shown to be 273 
associated with OC risk. Recently the population distribution of lifetime risks of OC was quantified by 274 
adding common genetic (SNP) risk factors to the known epidemiologic ones.[85] Eight combinations 275 
of risk factors gave a life time OC risk ≥5% and 2% of the US population were found to have a lifetime 276 
risk ≥5%.[85] Development and validation of new models for OC risk prediction and population 277 
stratification is also the subject of ongoing research in the PROMISE (Predicting Risk of Ovarian 278 
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Malignancy Improved Screening and Early detection) programme.[88] Such an approach 279 
incorporating polygenic risk information has also been suggested for BC, where it is estimated that 280 
11% of the population representing 34% of cases can be identified[84] for targeted 281 
chemoprevention.[89] 282 
 283 
Rising health care costs and ever increasing price of new cancer treatments/drug therapies in a 284 
challenging economic environment further magnify the importance of newer cost-effective 285 
preventive strategies. Development of such models provides hope for the principle of using risk 286 
stratification for the purpose of targeted primary prevention and early detection.  Currently the 287 
most effective method of preventing OC is risk reducing salpingo-oophorectomy (RRSO), with a 288 
reported hazard ratio (HR) for the procedure of 0.06 (CI:0.02,0.17) in a low-risk population[90] and 289 
0.21 (CI:0.12,0.39) in high-risk BRCA1/BRCA2 carriers.[13] However, surgical prevention in current 290 
clinical practice (RRSO) is usually only available as a primary prevention strategy to high risk women 291 
(life time risk >10%). The precise risk threshold at which RRSO should be undertaken for OC 292 
prevention needs review in the context of evaluating and implementing a population based OC risk 293 
stratification strategy. We speculate that it is likely this will lie well below the current accepted 294 
practice of 10% risk. Although Screening for OC has not yet been shown to reduce mortality,[91] 295 
incidence screening results from the UKCTOCS study published recently indicate that screening using 296 
the risk of ovarian cancer algorithm (ROCA) doubled the number of screen-detected epithelial OC 297 
compared with a fixed Ca125 cut-off[92]. Mortality outcome results from the trial are expected to be 298 
published at the end of 2015. Should a mortality effect be demonstrated, a risk based appropriately 299 
targeted OC screening programme would become feasible. Evaluation of any population strategy 300 
needs to incorporate chemoprevention options such as use of the pill[93] and other factors like 301 
aspirin[86] being identified through pooled analyses for OC, as well as Tamoxifen for BC.[89] 302 
Although current models offer limited discrimination, they do permit identification of a higher risk 303 
sub-group, towards whom effective clinical interventions may be targeted. This can contribute 304 
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towards reducing the burden of disease in the population. The falling cost of genetic testing coupled 305 
with sophisticated modelling and emergence of better defined cost-effective therapeutic 306 
interventions will enable implementation of such a strategy for OC and other cancers, including BC in 307 
the near future. However, further research confirming ‘clinical validity’ and ‘clinical utility’ of this 308 
approach is needed before widespread implementation of such a population screening and 309 
stratification strategy.  310 
 311 
Genetic Counselling  312 
Pre-test genetic counselling reduces distress, improves patients’ risk perception[31] and remains 313 
part of international guidelines prior to genetic testing.[47] All participants in the GCaPPS population 314 
study received pre-test and post-test counselling. Unlike GCaPPS,[2] the Israeli[3] and Canadian[4] 315 
studies did not provide pre-test counselling but reported high satisfaction with the population 316 
testing process. ‘Pre-test counselling’ has not yet been directly compared to an approach of ‘no pre-317 
test counselling’ or only ‘post-test counselling’ in a randomised trial. Newer approaches like 318 
telephone counselling,[94, 95] DVD based counselling[96] have been found to be non-inferior and 319 
cost-efficient compared to standard face to face counselling. There is widespread recognition that 320 
successful implementation of case series testing requires a move away from the standard face-to-321 
face genetic counselling approach. Informed consent and pre-test counselling needs to be delivered 322 
by the non-cancer genetics professional community. Different models being explored for this 323 
purpose include mainstreaming[97] and use of dedicated trained nurse specialists co-ordinated 324 
through a regional genetics service.[98] However, data comparing outcomes of these approaches 325 
are lacking. Efficient, acceptable, and cost-effective ways of delivering information on genetic risk 326 
will be needed for the successful implementation of any population-based testing program and this 327 




Specific attention also needs to be paid to pre-test counselling and post-test counselling of results in 330 
the context of panel testing. This is more complicated given the large number of genes, some 331 
without precise risk estimates or interventions of proven clinical benefit for identified carriers. In 332 
addition uncertainty exists on how to deal with variants of uncertain significance (VUS)/ incidental 333 
findings, the identification of which will increase with the number of genes tested. Results of 334 
clinically significant mutations of sufficient risk need to be returned to participants and it is 335 
important for the possibility of incidental findings as well as plans for disclosure/non-disclosure to be 336 
discussed with participants at the outset. New approach(es) to counselling for informed consent 337 
such as a ‘tiered and binned’ approach are being explored.[99] Information is organised into 338 
clinically relevant ‘bins’ and levels (‘tiers’) of detail given out are dependent on an individual’s needs 339 
to make an informed decision. Given the potential complexity and interpretation of results, pros and 340 
cons need to be carefully discussed with patients by experienced and well-informed health 341 
professionals.[100] Specific tools/decision aids to facilitate understanding of risk and informed 342 
consent need to be developed for panel testing and any population testing strategy. In addition, the 343 
use of adjuncts like DVDs, helplines and telephone counselling approaches are yet to be evaluated 344 
outside a single gene setting. 345 
 346 
Direct to Consumer (DTC) genetic testing 347 
 348 
Technological and scientific developments over the last few years have led to a number of 349 
companies offering a range of genetic testing services for common genetic variants as well as rare 350 
and high penetrance single gene disorders. These services are sold directly to consumers through 351 
avenues outside the traditional health system such as via the internet, television or other means. 352 
Driven by aggressive advertising and increasing awareness, the commercial market for this has been 353 
growing at a rapid rate. Proponents of DTC testing point to increased consumer access, consumer 354 
autonomy and empowerment as advantages. A number of professional bodies, authorities, scientists 355 
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and individuals have highlighted concerns regarding this. These concerns relate to the quality, 356 
analytic utility, clinical utility and validity of the scientific data that forms the basis of a number of 357 
reports provided by DTC companies.[101, 102] The European Society of Human Genetics (ESHG), 358 
American Society of Clinical Oncology (ASCO) and American Society of Human Genetics (ASHG) 359 
published formal policy guidelines regarding DTC testing and advertising.[102-104] Some argue that 360 
regulation and laws cannot guarantee responsible use. However a voluntary international product 361 
quality assurance certificate along the lines of ISO could control for compliance with ethical 362 
standards, counselling, scientific validity, provide commercial advantages to DTC companies and be a 363 
better option.[105] Nevertheless, there remains widespread concern in the professional community 364 
regarding overstatement of effectiveness, minimization of risks, lack of ‘informed’ consent, data 365 
protection issues and overselling of tests by DTC companies. There is also uneasiness and 366 
apprehension about the lack of adequate pre-test information and post-test counselling, leading to 367 
inappropriate health outcomes/ detrimental consequences. Although smaller market players 368 
remain, three of the larger players have stopped offering it. Navigenics and deCODEme stopped 369 
when they were sold and 23andMe discontinued marketing of their personal genome service under 370 
FDA orders in November 2013.[106] While a number of scientists and clinicians welcomed this 371 
step,[107, 108] some critics deemed it to be paternalistic, over-cautious, damaging to commercial 372 
free-speech and patient empowerment.[109] The debate will continue. 373 
 374 
Future Perspectives 375 
 376 
Going forward, further validation studies will provide more precise risk estimates for a number of 377 
the newer gene mutations. Absolute risk values derived from relative risk estimates will be made 378 
available for the purpose of counselling/informed consent for genes for which they are yet 379 
unavailable. We speculate that redefined thresholds for interventions like RRSO will enable 380 
implementation of cost effective surgical prevention strategies for moderate penetrance OC genes. 381 
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Emergence of validated data in the not too distant future will lead to widespread clinical 382 
implementation of panel testing for genes like RAD51C, RAD51D, BRIP1, PALB2, CHEK2, ATM, etc. in 383 
women with strong FH of cancer and cancer case series. Although some have suggested that 384 
population based testing for BRCA1/BRCA2 genes could now be introduced into the general non-385 
Jewish population,[110] this is still premature as data on acceptability, clinical validity and cost-386 
effectiveness are lacking and implementation studies have not been undertaken. However, this will 387 
happen in the future once these studies are undertaken. Validated models incorporating 388 
combination(s) of a range of genetic (high, moderate and low penetrant) and epidemiologic/ 389 
environmental factors will become available for clinical implementation. As new risk variants are 390 
discovered, the performance of risk prediction models will get refined and improve. It is important 391 
for epigenomic data to also be incorporated into risk prediction models and the large data sets 392 
needed to facilitate this require developing. With the declining costs of sequencing, the use of gene-393 
panel testing, as well as whole-exome and whole-genome sequencing, will become more 394 
widespread. Large scale prospective studies of general population based testing for a panel of cancer 395 
genes/genetic variants as well as epidemiologic factors incorporated into risk prediction algorithms 396 
will need to be undertaken to evaluate clinical utility, acceptability, impact on psychological health 397 
and quality of life, uptake of preventive strategies, as well as cost-effectiveness, delivery pathways, 398 
and long term health outcomes. An initial small pilot study for OC is proposed to commence along 399 
these lines in 2016 within the PROMISE grant.[88]  400 
 401 
Integration into P4 Medicine and Precision Medicine 402 
 403 
‘P4 medicine’ consists of Predictive, Preventive, Personalized, and Participatory medicine.[111] 404 
‘Precision medicine’ includes development of prevention and treatment strategies that take 405 
individual variability into account.[112] Systems medicine driven approaches incorporating genomic 406 
information (genomic medicine) along with appropriate biological and computational tools for data 407 
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interpretation will be used to deliver P4 and Precision medicine in the future. This will enable 408 
introduction of individualised tailored prevention and/or treatment strategies. Integration and 409 
implementation of a population screening strategy for collecting genomic and epidemiologic 410 
information will be essential for the application of P4/Precision medicine approaches for cancer 411 
prevention and treatment. Our current health care systems are concentrated primarily on treatment 412 
of disease. They are not focused on prediction /prevention and maintaining ‘wellness’. Delivery of a 413 
P4/Precision medicine approach incorporating population based testing will require a big change in 414 
focus. While precision medicine delivered treatment strategies for those with cancer are likely to 415 
remain hospital led, approaches for prediction and prevention will require a move away from 416 
hospitals and clinics to the community/high-street and/or home environment. It will involve use of 417 
new and innovative information tools, resources, devices, apps and health information systems for 418 
individuals to proactively participate in managing their health. It will also require the development of 419 
new care pathways and relationships between participating individuals and healthcare providers. 420 
Providers need to deliver predictive information as well as develop downstream management 421 
pathways for delivering effective risk-reducing clinical interventions for the at-risk population and 422 
monitoring long term health outcomes. Different solutions are likely to emerge for different 423 
countries and commercial companies offering newer DTC models with built in safeguards. In 424 
addition appropriate oversight/regulatory framework will need to be integrated into this process to 425 
maximise possible impact for population benefit. Education of the public/ consumers as well as 426 
general practitioners, genetic clinicians, gynaecologists, health care providers and stake holders 427 
involved in management of these women remains a massive challenge which also needs addressing. 428 
In January 2015, President Obama announced a precision medicine initiative with cancer as an 429 
important component within the scheme.[113] Many more such initiatives and funding streams 430 
driven innovative research studies are needed to fulfil its potential.  431 
 432 
EXECUTIVE SUMMARY 433 
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• The traditional family-history based approach for genetic testing has limitations and misses 434 
>50% mutation carriers. It is being replaced by population-based approaches for genetic testing.  435 
• Population-based BRCA1/BRCA2 testing in Ashkenazi Jews does not cause psychological harm 436 
and identifies more people at risk, reduces breast and ovarian cancer incidence and is extremely 437 
cost effective. This supports a change in the clinical paradigm in this population.  438 
• Population-based testing of cancer case series is becoming more widespread. However, lack of 439 
funding and awareness amongst clinicians is preventing harmonised implementation. Its 440 
successful application requires counselling with new approaches like mainstreaming, involving 441 
the non cancer genetics clinical community.  442 
• The availability of high throughput technologies has led to multiplex panel testing becoming 443 
available in clinics. However, a number of genes being tested in these panels lack precise cancer 444 
risk estimates and uncertainty exists on how to deal with VUS and incidental findings. Pros and 445 
cons need to be carefully discussed with patients by experienced and well-informed health 446 
professionals. 447 
• A number of newer intermediate/ moderate penetrance genes and common genetic variants 448 
have recently been identified for ovarian, breast and other cancers. Development of 449 
sophisticated risk models incorporating genomic and epidemiologic information coupled with 450 
availability of high throughput technology for genetic testing and falling costs provides 451 
opportunity for using risk stratification for the purpose of targeted primary prevention and early 452 
detection.  453 
• There has been widespread concern in the professional community regarding overstatement of 454 
effectiveness, minimization of risks, lack of ‘informed’ consent, data protection issues and 455 
overselling of tests by DTC companies. The appropriateness of DTC and need for proper 456 
regulation and safe-guards remains a matter of ongoing debate.  457 
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• In the near future, emergence of validated data will lead to widespread clinical implementation 458 
of panel testing for moderate penetrance genes like RAD51C, RAD51D, BRIP1, PALB2, CHEK2, 459 
ATM, etc. in women with strong FH of cancer and OC/BC cancer case series. 460 
• Large scale prospective studies of general population based testing for a panel of cancer 461 
genes/genetic variants as well as epidemiologic factors incorporated into risk prediction 462 
algorithms need to be undertaken to  evaluate clinical utility, acceptability, impact on 463 
psychological health/ quality of life, cost-effectiveness and long term health outcomes. 464 
• Systems medicine driven approaches incorporating genomic information (genomic medicine) 465 
along with appropriate biological and computational tools for data interpretation will be used to 466 
deliver P4 and Precision medicine in the future. This will enable introduction of individualised 467 
tailored prevention and/or treatment strategies. 468 
 469 
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